This segment focuses on the development and commercialization of blood-based diagnostic tests for the early detection, monitoring, and prognosis of various human cancers. VolitionRx utilizes its proprietary Nu.Q® platform, which leverages the analysis of circulating nucleosomes and their epigenetic modifications, to identify cancer-specific biomarkers. Research and development efforts are directed towards expanding the range of cancers detectable by the Nu.Q® platform and improving the accuracy and sensitivity of the tests. Clinical trials are conducted to validate the performance of the Nu.Q® tests in diverse patient populations. The goal is to provide clinicians with a non-invasive, cost-effective tool for improving cancer outcomes through earlier diagnosis and personalized treatment strategies. Future opportunities include expanding into new markets and developing companion diagnostics for targeted cancer therapies.

This segment is dedicated to the development and commercialization of diagnostic tests for cancer in animals, particularly companion animals such as dogs and cats. The company's Nu.Q® Vet Cancer Screening Test is designed to provide veterinarians with a simple, affordable, and accurate method for detecting cancer in its early stages. Research and development efforts are focused on expanding the range of animal cancers detectable by the Nu.Q® platform and developing new tests for disease monitoring and treatment response. The company is also working on a point-of-care platform to enable rapid testing in veterinary clinics. The veterinary diagnostics market represents a significant growth opportunity for VolitionRx, as pet owners increasingly seek advanced medical care for their animals. Future opportunities include expanding into new geographic markets and developing partnerships with veterinary hospitals and diagnostic laboratories.

This segment focuses on the development of diagnostic tests targeting Neutrophil Extracellular Traps (NETs), which are implicated in various inflammatory and autoimmune diseases, as well as cancer and sepsis. VolitionRx is developing Nu.Q® NETs tests to quantify NETs biomarkers in blood samples, providing clinicians with a tool for diagnosing and monitoring these conditions. Research and development efforts are directed towards identifying novel NETs-related biomarkers and developing assays for point-of-care testing. Clinical studies are being conducted to validate the performance of the Nu.Q® NETs tests in sepsis and other critical illnesses. The company aims to establish itself as the leading provider of NETs-based diagnostics, offering solutions for early detection, risk stratification, and treatment monitoring. Future opportunities include expanding into new therapeutic areas and developing partnerships with pharmaceutical companies to support the development of NETs-targeted therapies.